Aggregation of amyloid-β (Aβ) into oligomers, fibrils, and plaques is central in the molecular
pathogenesis of Alzheimer's disease (AD), and is the main focus of AD drug development …

In the 12 years since the publication of the first Consensus Paper of the WFSBP on
biomarkers of neurodegenerative dementias, enormous advancement has taken place in …

In the past 8 years, both the International Working Group (IWG) and the US National Institute
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …

Background Our objective was to evaluate the efficacy (clinical and biomarker) and safety of
intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease (AD) …

Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20
years) and an average clinical duration of 8–10 years. The disease has an estimated …

The lack of readily available biomarkers is a significant hindrance toward progressing to
effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based …

Background According to the latest revised National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders …

Ironically, population aging which is considered a public health success has been
accompanied by a myriad of new health challenges, which include neurodegenerative …

Recently, low-sensitive plasma assays have been replaced by new ultra-sensitive assays
such as single molecule enzyme-linked immunosorbent assay (Simoa), the Mesoscale …

Here we describe an update of the Therapeutic Target Database (http://bidd. nus. edu.
sg/group/ttd/ttd. asp) for better serving the bench-to-clinic communities and for enabling …